NCT06609876View on ClinicalTrials.gov

Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

NARecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2028

Conditions
Hepatocellular CarcinomaMicrowave AblationDonafenibRecurrent Tumor
Interventions
PROCEDURE

Thermal ablation

Thermal ablation of tumors

DRUG

Donafenib

Donafenib ( 100 mg，bid)

Trial Locations (1)

100853

RECRUITING

Chinese PLA General hospital, Beijing

All Listed Sponsors
collaborator

Chinese PLA General Hospital

OTHER

lead

Sun Yat-sen University

OTHER